<DOC>
	<DOC>NCT00662610</DOC>
	<brief_summary>To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension</brief_summary>
	<brief_title>A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure</brief_title>
	<detailed_description>This is a 12-week, randomized, double-blind, multicenter study comparing the effect of naproxcinod and naproxen on 24 hour arterial blood pressure profile. Patients will be randomly allocated to different naproxcinod or naproxen doses in a 1:1 ratio.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Men/Women, 40 or older, diagnosed with hip or knee Osteoarthritis. Hypertensive patient with treated and controlled essential hypertension. Must receive at least one antihypertensive treatment from the following drug classes: Diuretic, AngiotensinConverting Enzyme (ACE) inhibitor, Angiotensin Receptor Blocker (ARB) or BetaBlocker (BB). Must be current chronic user of NSAIDS or acetaminophen. Must discontinue all analgesic therapy at Screening. More than two different classes of antihypertensive drugs. Uncontrolled diabetes. Hepatic or renal impairment. A history of alcohol/drug abuse. Diagnosis of gastric or duodenal ulceration and/or history of significant gastroduodenal bleeding. History of congestive heart failure. Clinically relevant abnormal ECG. Current or expected use of anticoagulants. Current or history of any medical disease that could interfere with the study objectives or put the patient's safety at risk. Participation within 30 days prior to prescreening in another investigational study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>